Hi QFHere it is:"CEO Peter CookFirst, we’ll be very carefully...

Hi QF

Here it is:

"CEO Peter Cook
First, we’ll be very carefully monitoring Relenza royalties each quarter and
informing our shareholders about that. Second, with laninamavir we’d expect
to see progress towards a rest-of-the-world partner and also to see progress
toward the commercial introduction of the product in Japan, including the
NDA submission and commencement of the prophylaxis study. Additionally,
we’ll see progress on the clinical studies of laninamivir underway in the West.
Third, we’d expect to see progress on the licensing of the HRV program and
fourth we’d expect progress around the Hepatitis C program we’ve licensed to
Boehringer Ingelheim, which we’ve not had a lot to say about in the recent
period.
In addition, we’ve spent a considerable amount of time on strategy in the last
few months and we’ve identified that as quickly as possible we want to be in
the position of having two or three products out in the market generating
royalties at any one point in time. That’s going to require the addition of
appropriate programs to our portfolio.
corporatefile."

http://www.biota.com.au/uploaded/154/1021550_52openbriefing-ceoonfy09r.pdf